Clinical Trial Update: Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, for advanced pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• hV01 (recombinant human IL-21-expressing oncolytic vaccinia virus)

Snippet

Sponsor: Hangzhou Converd Co., Ltd. | Conditions: Advanced Pancreatic Cancer | Phase 2 | Status: RECRUITING